Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 02:52pm CET
   By Victoria Stilwell 
 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
02/26 MERCK : Letermovir, an Investigational Antiviral Medicine for Prevention of Cyto..
02/24 MERCK : In First Phase 3 Trial, Merck’s Investigational Inactivated Varice..
02/24 MERCK : Study Findings from Merck & Company Broaden Understanding of Hepatitis C..
02/24 RECENT STUDIES FROM MERCK & COMPANY : A...
02/24 MERCK : Announces EPOCH Study of Verubecestat for the Treatment of People with M..
02/24 MERCK : New Data from Merck & Company Illuminate Findings in Immunoglobulins (Tr..
02/24 MERCK : Study Results from Merck & Company in the Area of Vaccines Reported (Des..
02/24 MERCK : Research Data from Merck & Company Update Understanding of Hypertension ..
02/24 DATA FROM MERCK & COMPANY ADVANCE KN : a snapshot of recent data in pediatric an..
02/24 MERCK : Researchers at Merck & Company Report New Data on Melanoma (Population P..
More news
Sector news : Pharmaceuticals - NEC
06:13p FTSE ends higher on some positive earnings, insurers slip
08:06aDJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07:38a Roche's Renal Success Spells Danger For All-Comer Studies
02/26 BIOTECH FORUM DAILY DIGEST : Can Aerie Pharmaceuticals Continue To Rally? Spotli..
02/24 Merck's VZV vaccine candidate successful in first late-stage study in immunoc..
02/24 SYNERGY : 3 Scenarios, 1 Choice
02/24 I'M SICK AND TIRED OF GILEAD SCIENCE : Part 2
Advertisement
Financials ($)
Sales 2017 39 712 M
EBIT 2017 13 517 M
Net income 2017 8 459 M
Debt 2017 4 774 M
Yield 2017 2,84%
P/E ratio 2017 20,23
P/E ratio 2018 17,19
EV / Sales 2017 4,71x
EV / Sales 2018 4,56x
Capitalization 182 412 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,7 $
Spread / Average Target 3,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.12.38%182 412
JOHNSON & JOHNSON6.53%333 891
ROCHE HOLDING LTD.5.42%210 192
PFIZER INC.5.48%207 902
NOVARTIS AG4.72%202 648
SANOFI4.79%109 848
More Results